Outcomes of Stereotactic Body Radiotherapy for T1-2 N0 Small Cell Carcinoma Based on Addition of Chemotherapy and Prophylactic Cranial Irradiation: A Multicenter Analysis

摘要

T1–2N0 SCLC is rare, but is often treated with SBRT alone similar to T1–2N0 NSCLC. This multi-center study assessed whether additional chemo/PCI improves outcomes. Chemotherapy improved DFS and OS and predicted for both on multivariate analysis. PCI was not statistically associated with outcomes herein. This analysis suggests that T1–2N0 SCLC should be treated as limited-stage SCLC.BACKGROUND:Whereas T1–2 N0 non-small cell lung cancer (NSCLC) can be managed with stereotactic body radiotherapy (SBRT) alone, this management is often extrapolated for T1–2 N0 small cell lung cancer (SCLC). This multi-institutional cohort study investigated whether addition of chemotherapy and PCI improved outcomes for these patients.